KLHDC3: A Potential Drug Target and Biomarker (G116138)

Target Name: KLHDC3

NCBI ID: G116138

KLHDC3: A Potential Drug Target and Biomarker

Kelch domain containing 3 (KLHDC3) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the Kelch family of proteins, which are involved in various cellular processes, including intracellular signaling, cell division, and DNA replication. KLHDC3 has been identified as a potential drug target and biomarker due to its unique structure and expression pattern.

The Kelch family of proteins is characterized by the presence of a catalytic Kelch domain and a variable region that includes a heparan sulfate (HSP) domain and a carboxylic acid (CA) domain. KLHDC3 is a 16-kDa protein that contains a single copy of the HSP domain and a single copy of the CA domain. The HSP domain is known for its ability to form a stable covalent complex with various molecules, including small molecules, ions, and other proteins. The CA domain is involved in the regulation of protein -protein interactions and is known for its ability to interact with the HSP domain.

KLHDC3 is expressed in various tissues and cells throughout the body, including the brain, heart, liver, and gastrointestinal tract. It is highly expressed in the liver, with lower levels observed in the heart and brain. KLHDC3 is also expressed in various cell types , including liver cells, glomerular epithelial cells, oral epithelial cells and intestinal epithelial cells, etc.

KLHDC3 has been identified as a potential drug target due to its unique structure and expression pattern. The HSP domain of KLHDC3 is known for its ability to form stable covalent complexes with various molecules, including small molecules, ions, and other proteins. This makes KLHDC3 a potentially attractive drug target for various diseases, including neurodegenerative disorders, cardiovascular diseases, and gastrointestinal diseases.

In addition to its potential as a drug target, KLHDC3 has also been identified as a biomarker for various diseases. The liver is a key organ that is involved in the detoxification and metabolism of various substances in the body. As a result, changes in the expression patterns of KLHDC3 in the liver could be an indicator of various diseases, including neurodegenerative disorders, cardiovascular diseases, and gastrointestinal diseases.

KLHDC3 has been shown to be involved in the regulation of cellular processes that are important for the development and progression of various diseases. For example, studies have shown that KLHDC3 is involved in the regulation of neurogenesis, which is the process by which new neurons are produced in the brain. Additionally, KLHDC3 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body.

KLHDC3 has also been shown to be involved in the regulation of cellular signaling pathways that are important for the development and progression of various diseases. For example, studies have shown that KLHDC3 is involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling pathways that are important for the development and progression of various diseases, including neurodegenerative disorders and cardiovascular diseases.

In conclusion, KLHDC3 is a protein that is expressed in various tissues and cells throughout the body. It is a member of the Kelch family of proteins and has been identified as a potential drug target and biomarker due to its unique structure and expression pattern. Further research is needed to determine the full potential of KLHDC3 as a drug target and biomarker for various diseases.

Protein Name: Kelch Domain Containing 3

Functions: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948, PubMed:29775578). The CRL2(KLHDC3) complex specifically recognizes proteins with a glycine (Gly) at the C-terminus, leading to their ubiquitination and degradation: recognizes the C-terminal -Arg-(Xaa)n-Arg-Gly, -Arg-(Xaa)n-Lys-Gly, and -Arg-(Xaa)n-Gln-Gly degrons (PubMed:29779948, PubMed:29775578). The CRL2(KLHDC3) complex mediates ubiquitination and degradation of truncated SELENOV and SEPHS2 selenoproteins produced by failed UGA/Sec decoding, which end with a glycine (PubMed:26138980). May be involved in meiotic recombination process (PubMed:12606021)

More Common Targets